These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 1434911)

  • 1. Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study.
    Steadman CJ; Talley NJ; Phillips SF; Zinsmeister AR
    Mayo Clin Proc; 1992 Aug; 67(8):732-8. PubMed ID: 1434911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GR 38032F (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man.
    Talley NJ; Phillips SF; Haddad A; Miller LJ; Twomey C; Zinsmeister AR; MacCarty RL; Ciociola A
    Dig Dis Sci; 1990 Apr; 35(4):477-80. PubMed ID: 2138532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia?
    Maxton DG; Morris J; Whorwell PJ
    Aliment Pharmacol Ther; 1996 Aug; 10(4):595-9. PubMed ID: 8853764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron).
    Goldberg PA; Kamm MA; Setti-Carraro P; van der Sijp JR; Roth C
    Digestion; 1996; 57(6):478-83. PubMed ID: 8913711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome.
    Prather CM; Camilleri M; Zinsmeister AR; McKinzie S; Thomforde G
    Gastroenterology; 2000 Mar; 118(3):463-8. PubMed ID: 10702196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea.
    Garsed K; Chernova J; Hastings M; Lam C; Marciani L; Singh G; Henry A; Hall I; Whorwell P; Spiller R
    Gut; 2014 Oct; 63(10):1617-25. PubMed ID: 24334242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of irritable bowel syndrome with diarrhoea using titrated ondansetron (TRITON): study protocol for a randomised controlled trial.
    Gunn D; Fried R; Lalani R; Farrin A; Holloway I; Morris T; Olivier C; Kearns R; Corsetti M; Scott M; Farmer A; Emmanuel A; Whorwell P; Yiannakou Y; Sanders D; Mclaughlin J; Kapur K; Eugenicos M; Akbar A; Trudgill N; Houghton L; Dinning PG; Ford AC; Aziz Q; Spiller R
    Trials; 2019 Aug; 20(1):517. PubMed ID: 31429811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-HT4 receptor antagonism in irritable bowel syndrome: effect of SB-207266-A on rectal sensitivity and small bowel transit.
    Houghton LA; Jackson NA; Whorwell PJ; Cooper SM
    Aliment Pharmacol Ther; 1999 Nov; 13(11):1437-44. PubMed ID: 10571599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of irritable bowel syndrome: novel approaches to the pharmacology of gut motility.
    Scarpignato C; Pelosini I
    Can J Gastroenterol; 1999 Mar; 13 Suppl A():50A-65A. PubMed ID: 10202210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bimodal Release Ondansetron Improves Stool Consistency and Symptomatology in Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Trial.
    Plasse TF; Barton G; Davidson E; Abramson D; Kalfus I; Fathi R; Raday G; Harris MS
    Am J Gastroenterol; 2020 Sep; 115(9):1466-1473. PubMed ID: 32639235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colonic transit, bowel movements, stool form, and abdominal pain in irritable bowel syndrome by treatments with calcium polycarbophil.
    Chiba T; Kudara N; Sato M; Chishima R; Abiko Y; Inomata M; Orii S; Suzuki K
    Hepatogastroenterology; 2005; 52(65):1416-20. PubMed ID: 16201086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome?
    Sweetser S; Camilleri M; Linker Nord SJ; Burton DD; Castenada L; Croop R; Tong G; Dockens R; Zinsmeister AR
    Am J Physiol Gastrointest Liver Physiol; 2009 Jun; 296(6):G1299-306. PubMed ID: 19342506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome.
    Kim HJ; Camilleri M; McKinzie S; Lempke MB; Burton DD; Thomforde GM; Zinsmeister AR
    Aliment Pharmacol Ther; 2003 Apr; 17(7):895-904. PubMed ID: 12656692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome.
    Thumshirn M; Coulie B; Camilleri M; Zinsmeister AR; Burton DD; Van Dyke C
    Aliment Pharmacol Ther; 2000 Jul; 14(7):869-78. PubMed ID: 10886042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.
    Andresen V; Camilleri M; Busciglio IA; Grudell A; Burton D; McKinzie S; Foxx-Orenstein A; Kurtz CB; Sharma V; Johnston JM; Currie MG; Zinsmeister AR
    Gastroenterology; 2007 Sep; 133(3):761-8. PubMed ID: 17854590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers.
    Houghton LA; Foster JM; Whorwell PJ
    Aliment Pharmacol Ther; 2000 Jun; 14(6):775-82. PubMed ID: 10848662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abnormalities of GI transit in bloated irritable bowel syndrome: effect of bran on transit and symptoms.
    Hebden JM; Blackshaw E; D'Amato M; Perkins AC; Spiller RC
    Am J Gastroenterol; 2002 Sep; 97(9):2315-20. PubMed ID: 12358250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Visceral perception in irritable bowel syndrome. Rectal and gastric responses to distension and serotonin type 3 antagonism.
    Zighelboim J; Talley NJ; Phillips SF; Harmsen WS; Zinsmeister AR
    Dig Dis Sci; 1995 Apr; 40(4):819-27. PubMed ID: 7720476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5-hydroxytryptamine receptor (type 3) antagonist.
    Gore S; Gilmore IT; Haigh CG; Brownless SM; Stockdale H; Morris AI
    Aliment Pharmacol Ther; 1990 Apr; 4(2):139-44. PubMed ID: 2151757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of a calcium channel blocker and antispasmodic in diarrhoea-predominant irritable bowel syndrome.
    Lu CL; Chen CY; Chang FY; Chang SS; Kang LJ; Lu RH; Lee SD
    J Gastroenterol Hepatol; 2000 Aug; 15(8):925-30. PubMed ID: 11022835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.